The changes of molecular markers with neoadjuvant dose-dense doxorubicin hydrochloride, cyclophosphamide, and paclitaxel chemotherapy regimen

Authors :: Yavuz Ozisik
D. Sener Dede
Kadri Altundag
Berrak Gumuskaya
D Onat
Gulnur Guler
Source :: Journal of Clinical Oncology. 28:e21028-e21028
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e21028 Background: The aim of this study was to assess the clinical response (complete clinical response and partial clinical response) (CR) and pathological complete response (no residual invasive...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Cyclophosphamide
business.industry
Chemotherapy regimen
chemistry.chemical_compound
Paclitaxel
chemistry
Internal medicine
medicine
Doxorubicin Hydrochloride
business
Complete response
medicine.drug

Full Text Access

Tools